Crizanlizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Crizanlizumab and local guidelines before prescribing.
P-selectin antagonist
Mechanism
P-selectin monoclonal antibody.
Uses
Sickle cell disease vaso-occlusive crisis prevention.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, headache, arthralgia.
Interactions
Few.
Contraindications and cautions
Hypersensitivity
Monitoring
Crisis frequency
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Monthly infusion.
More from the textbook: uses, cautions and other points
- Gene therapy (exagamglogene autotemcel) and stem cell transplant - for selected severe disease in specialist centres; some earlier new drugs (crizanlizumab, voxelotor) have been withdrawn in the UK or Europe.
Haematology: Anatomy Physiology and Pharmacology - Withdrawn drugs: Crizanlizumab and voxelotor were withdrawn in 2024 (lack of benefit, and safety concerns with voxelotor).
Haematology: Haemoglobinopathies and Transfusion - Hydroxycarbamide is the key disease-modifying drug; penicillin and vaccines for hyposplenism. Crizanlizumab and voxelotor were withdrawn in 2024.
Haematology: Haemoglobinopathies and Transfusion - Treatment - analgesia within 30 minutes for crises (NICE CG143), fluids, oxygen if hypoxic; hydroxycarbamide (raises HbF); transfusion and exchange transfusion; crizanlizumab (withdrawn in the UK); stem cell transplant ; gene therapy - exagamglogene autotemcel (Casgevy - CRISPR gene editing) approved for selected patients.
Clinical Genetics: Single-gene, repeat-expansion and mitochondrial disorders